we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Congress 2022 demonstrating how EndoPredict can help guide treatment decisions and avoid overtreatment for premenopausal women with ER+, HER2- early breast cancer.
Eurobio Onclogy
News & Blogs
Home > ESMO 2022 Symposium
Watch Myriad Genetics’ ESMO 2022 Industry Satellite Symposium
September 19, 2022